Alembic Pharma delivered a better than expected operational performance, led by better-than-industry growth in the Domestic Formulations (D...

In an interview to ET, Pranav Amin, Managing Director of Alembic Pharmaceuticals said the management still remains bullish on the US market...

The company had posted a net profit of Rs 333.37 crore for the corresponding period of the previous fiscal, Alembic Pharmaceuticals said in...

Earlier this month, the US drug regulator had issued a ‘Form 483’ to the facility of the drug company with five observations.

As per the USFDA, a Form 483 is issued to a firm's management at the conclusion of an inspection when an investigator has observed any cond...

USFDA issued a form 483 with two observations, the drug firm said in a filing to BSE.

Stock may see a sell-off on earnings downgrades & FDA warning, but co has not revised revenue guidance & FIs have steadily raised holdings.

The US is the largest market for domestic generic companies, contributing 25-55% of revenues for large companies, while India supplies arou...

Sun Pharma has 15 days time to reply to the various concerns raised by the FDA related to the plant.

The Sun-Ranbaxy combined entity will unlock the true potential of the Gurgaon based company, says former Ranbaxy owner Malvinder Singh.

Ranbaxy to open higher after Sun Pharma said it will buy generic drug maker in an all-share deal with total equity value of $3.2 bn.

Rejecting US allegations related to intellectual property rights, India said that it is ready to discuss the matter at WTO as it has not br...

Shares of Sun Pharma continued to remain under pressure for second straight session after the USFDA issued an Import Alert to its plant.

Facilities of leading Indian drugmakers including Ranbaxy and Wockhardt were blacklisted by the US regulator last year.

Shares of Sun Pharmaceutical declined over 5% to Rs 573.60 after US FDA banned imports from Indian generic drugmaker’s plant at Karkhadi in...

Shares of Sun Pharmaceutical Industries today fell by over 5 per cent after the US Food and Drug Administration banned import of drugs from...

Ranjit Kapadia an analyst at Centrum Broking doesn’t see more than 4-5 per cent revenue hit for the company due to import alert.